Eris Lifesciences Ltd Board of Directors

Members of the ERIS Lifesciences Ltd Board of Directors are typically selected based on their expertise, experience, and alignment with ERIS Lifesciences Ltd’s strategic goals. Appointments are made by the nomination and remuneration committee and approved by shareholders. However, the selection process does vary from company to company.

Shareholders can interact with the ERIS Lifesciences Ltd Board of Directors during the Annual General Meeting (AGM) and through formal communications or queries submitted to the company wherein they have the opportunity to ask questions and provide feedback on the business. Please note different companies have different protocols for shareholders who want to meet the Board of Directors.

The ERIS Lifesciences Ltd Board of Directors typically meets quarterly. However, special meetings may be summoned as needed to address urgent matters. The frequency can vary depending on business needs and regulatory requirements to ensure ongoing oversight and strategic guidance for the company. A scheduled meeting among the Board of Directors may vary from company to company.

The ERIS Lifesciences Ltd Board of Directors is responsible for setting strategic goals, overseeing company performance, ensuring effective governance, and safeguarding shareholder interests. They provide high-level guidance on corporate policies and risk management. Additionally, they appoint and evaluate senior management and ensure compliance with legal and regulatory requirements. Please note the roles and responsibilities of the Board of Directors may be different from company to company.

The current Board of Directors at ERIS Lifesciences Ltd includes Amit Indubhushan Bakshi( Chairman & Managing Director) ,Kaushal Kamlesh Shah( Whole-time Director) ,Inderjeet Singh Negi( Whole-time Director) ,Krishnakumar Vaidyanathan( Whole Time Director & COO) ,Sujesh Vasudevan( Independent Non Exe. Director) . The full list can be found on ERIS Lifesciences Ltd’s official website or recent corporate filings.